The cost of endemic malaria to Africa is overwhelming. Yet the effects of the disjointed, unfocused and mainly misdirected control efforts are visible and significant. We saw 216 Million case of malaria in 2011 and had 650000 deaths due to malaria in the same timeframe. When compared with almost 250 Million cases and 863000 deaths just a short three years earlier, the effect is clear. In spite of the plethora of effective tools available to us, the elimination of malaria will largely remain a pie in the sky.
This study, in a high transmission area of South Mali, explores whether residual parasitaemia at day 28 was associated with subsequent malaria episodes and/or anaemia.
This disappointment and the successful use of natural compounds emerging from traditional medicine for the chemotherapy of malaria (quinine, artemisnin) have invigorated the search for new antimalarials from natural sources. Hundreds of thousands compounds were screened and some promising leads were identified.
This study explored stakeholders' perceptions of the role of private medicine retailers (PMRs), the value and feasibility of programme goals, perceived programme impact, factors influencing implementation and recommendations in three districts of Kenya.
Recent advances in genome-based technologies and in in vitro screening of whole parasites have broadened the range of therapeutic targets and are accelerating the development of a new generation of treatments for both malaria control and eradication.